Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amazon.com Inc.

www.amazon.com

Latest From Amazon.com Inc.

Exec Chat: ResMed's CEO Mick Farrell Outlines 2025 Strategy For 250 Million Users

ResMed's CEO Mick Farrell outlined the company's 2025 strategy: double-digit growth, drive up its user base to 250 million people and becoming the leading digital health company in both sleep apnea and chronic obstructive pulmonary (COPD) disease. Medtech Insight sat down with Farrell at ResMed's San Diego headquarters to learn more.

Exec Chat Digital Health

Amazon's Alexa To Offer UK Health Advice – But Critics Raise Privacy Fears

The UK government has struck a deal with Amazon to make NHS-verified health advice available to users of the Alexa digital assistant. It says the move will help consumers to self-care with reliable healthcare information. However, detractors have questioned the government's motives and raised data privacy fears.
Artificial Intelligence Digital Health

Geisha-Inspired Tatcha Is Unilever's Latest US Prestige Skin-Care Addition

Unilever acquires ‘modern, prestige’ skin care firm Tatcha in a reported $500m deal. Tatcha's comprises dozens of items formulated with green tea, rice and algae. Unilever continues seeking beauty and personal care deals, which accounted for 70% of its acquired turnover in recent years.

M & A Cosmetics

Perrigo's Turnaround Tools: 'National Brand,' Novel NRTs, CBD And Natural Products, Sponsoring OTC Switches

Following investor day conference, market analysts gave Perrigo points for an ambitious three-year plan while also noting the degree of difficulty it faces in succeeding. Other changes planned to stem slump sales and earnings slump include potentially getting into CBD supplement space and getting back into VMS manufacturing after leaving the sector in one of several moves since 2015 intended to help drive net income and improve its margin.

OTC Drugs Business Strategies
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register